Company Profile for Dynavax Technologies
Feb 27, 2009 (BUSINESS WIRE) -- Dynavax Technologies Corporation, a clinical-stage biopharmaceutical company, discovers and develops a diversified pipeline of novel Toll-like Receptor (TLR) based product candidates. Based on Dynavax's proprietary technologies, these products specifically modify the innate immune response to infectious, respiratory, autoimmune, and inflammatory diseases. Dynavax has partnerships with leading pharmaceutical companies such as GlaxoSmithKline, AstraZeneca AB, and Novartis as well as funding from Symphony Dynamo, Inc. and the National Institutes of Health. For more information visit www.dynavax.com.
Company: | Dynavax Technologies | |
Headquarters Address: | 2929 Seventh Street, Suite 100 | |
| Berkeley, CA 94710 | ||
Main Telephone: | 510-848-5100 | |
Website: | ||
Ticker: | DVAX(NASDAQ) | |
Type of Organization: | Public | |
Industry: | Biotechnology | |
Key Executives: | CEO: Dino Dina | |
CFO: Deborah Smeltzer | ||
Investor Relations | ||
Contact: | Amy Figueroa | |
Phone: | 510-848-5100 | |
Email: |
SOURCE: Dynavax Technologies Corporation
Copyright Business Wire 2009